2023 was a tough year for the biopharma sector, with numerous companies downsizing and restructuring their workforces to stay afloat. There are actually indications of Restoration, as mergers and acquisitions picked up through the pharmaceutical and everyday living sciences industry from the latter Portion of 2023 and also have continued https://sites.google.com/view/bio-sites/blog